Champions Oncology


Recent Posts

Champions Oncology Expands Global Biomarker Capabilities with Opening of European Laboratory at OpenZone Life Sciences Campus

Oct 20, 2021 10:23:23 AM / by Champions Oncology

Hackensack, NJ – October 20, 2021 – Champions Oncology (NASDAQ: CSBR), a technology-enabled research organization announced the opening of a European laboratory located in the renowned OpenZone Life Sciences Campus in Bresso, Italy, on the doorstep of Milan.

After launching preclinical and clinical GCLP-compliant biomarker services in 2019, Champions Oncology has rapidly grown to be a leader in the industry by providing scientific expertise, unparalleled quality, and innovative data analytics.

Read More →

Champions Oncology Reports Record Quarterly Revenue of $11.3 Million

Sep 14, 2021 2:33:55 PM / by Champions Oncology

Hackensack, NJ – September 13, 2021Champions Oncology, Inc. (Nasdaq: CSBR), leaders in transformative technology solutions utilized in drug discovery and development, today announced its financial results for its first quarter of fiscal 2022, ended July 31, 2021.

First Quarter and Recent Highlights: 

  • Record quarterly revenue of $11.3 million, an increase of 18% year over year
  • Reported non-GAAP income from operations, excluding stock-based compensation, depreciation and amortization, of $422,000
  • Validated 6 therapeutic discovery targets

Read More →

Champions Oncology Announces an Expanded Corporate Strategy to Include Drug Discovery and Development

Jul 26, 2021 8:50:14 AM / by Champions Oncology

Hackensack, NJ – July 26, 2021Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced today an expansion of its corporate strategy as they unveil their entry into the drug discovery and development space. Champions is organized as a dynamic ecosystem of business units centered around a world leading oncology research center that is based off a unique & proprietary set of data and experimental platforms. The corporate composition of the company includes three business units (1) the foundational Research Services Business, (2) the recently launched Research Software Business with its flagship product, Lumin Bioinformatics, and (3) the newly announced Discovery and Innovation Business.

Read More →

Champions Oncology Reports Quarterly Revenue of $10.6 Million

Jul 23, 2021 1:22:26 PM / by Champions Oncology

Hackensack, NJ - July 22, 2021 Champions Oncology, Inc. (NASDAQ:CSBR), engaged in creating transformative technology solutions to be utilized in drug discovery and development, today announced its financial results for the year and fourth fiscal quarter ended April 30, 2021.

Fourth Quarter and Fiscal Year 2021 Financial and Recent Business Highlights:

  • Record annual revenue of $41.0 million, an increase of 28% year-over-year

  • Developed in house computational target discovery expertise to discover novel therapeutic targets

  • Continued expansion of our Lumin SaaS platform

Read More →

Champions Oncology and BGI Americas Announce a Strategic Partnership to provide Mass Spectrometry Proteomics, Metabolomics, and multi-omic Data Analysis Solutions

Jun 15, 2021 9:15:31 AM / by Champions Oncology

Hackensack, NJ – June 15, 2021 –Champions Oncology (NASDAQ: CSBR), a technology-enabled research organization announced today that they have entered into a strategic partnership with BGI Americas.

Through this partnership, BGI will now have access to Champions’ Lumin Bioinformatics platform, a revolutionary data interpretation tool, to display and deliver proteomics data to their clients. By leveraging Lumin, BGI’s customers will be able to gain novel insights from their proteomics data using unique multi-omic datasets assembled from over 25,000 cancer patients. Lumin Bioinformatics allows oncology scientists and bioinformaticians to analyze and visualize cancer model public and proprietary datasets to illuminate the cellular dynamics of cancer, through specialized modules such as gene signatures, network viewers, synergy plots and even gene dependency mapper tools using AI machine learning technology.

Read More →

Champions Oncology Reports Record Quarterly Revenue of $10.8 Million

Mar 12, 2021 5:56:30 PM / by Champions Oncology

Hackensack, NJ – March 11, 2021 – Champions Oncology, Inc. (Nasdaq: CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery and development through data-driven research strategies and innovative pharmacology, biomarker and data platforms, today announced its financial results for the third fiscal quarter ended January 31, 2021.

Third Quarter and Recent Highlights:

  • Delivered record quarterly revenue of $10.8 million, an increase of 20% year over year
  • Reported non-GAAP income from operations, excluding stock-based compensation, depreciation and amortization, of $1.3 million
  • Expanded Lumin Bioinformatics proprietary SaaS platform with proteomic module integration
Read More →

Champions Oncology Announces Partnership with Code Ocean to Expand the Functionality of Lumin Bioinformatics

Jan 19, 2021 9:00:00 AM / by Champions Oncology

HACKENSACK, NJ – January 19, 2021 9AM - Champions Oncology, Inc. (Nasdaq: CSBR), a leading global oncology technology company that is transforming drug discovery and development through data-driven research strategies, announced today a partnership with Code Ocean to expand the functionality of its SaaS program, Lumin Bioinformatics. The partnership between Champions and Code Ocean will focus on enhancements involved in data integration and sharing workflows within the Lumin platform.  Users will now be equipped with a robust methodology for centralizing, storing, and organizing large amounts of their own code and data within Lumin, while leveraging single tenant hosting.  Users will have the ability to upload this information directly or utilize Champions’ computational services to assist with integration.  This new functionality establishes an entire new use case for Lumin and facilitates a customized experience for our clients.  Importantly, users will now have a method for secure and rapid data sharing, creating a strong collaboration workflow between scientists within their company.  These new applications transform Lumin into an enterprise-level solution, supporting Champions’ efforts to broaden the total available market.

Read More →

Champions Oncology Announces the Expansion of Lumin Bioinformatics: Now Featuring a Highly Valuable Set of Proteomic Data and Analytics

Jan 5, 2021 8:14:49 AM / by Champions Oncology

HACKENSACK, NJ – January 5, 2021 8:30AM - Champions Oncology, Inc. (Nasdaq: CSBR), a leading global oncology technology company that is transforming drug discovery and development through data-driven research strategies, announced today the expansion of its SaaS program, Lumin Bioinformatics. Since its launch, Champions has been adding to the data and functionality housed within Lumin, which now features 20,000+ datasets including rare and valuable quantitative phospho-proteomics.  To aid in the analysis of this proteomic data, engineers at Champions have also developed a unique and sophisticated set of analysis tools that enable researchers to unlock the power of this proteomic data.

Read More →

Champions Oncology Reports Record Quarterly Revenue of $10.1 Million

Dec 15, 2020 4:57:58 PM / by Champions Oncology

HACKENSACK, NJ / ACCESSWIRE / December 14, 2020 / Champions Oncology, Inc.

(NASDAQ:CSBR), a leading global oncology technology solutions provider engaged in transforming drug discovery through innovative pharmacology, biomarker and data platforms, today announced its financial results for the second fiscal quarter ended October 31, 2020.

Second Quarter and Recent Highlights:

  • Launched our Lumin Bioinformatics proprietary SaaS platform
  • Delivered record quarterly revenue of $10.1 million, an increase of 33% year-over-year
  • Reported income from operations, excluding stock-based compensation, depreciation and amortization, of $400,000
  • Raising our full-year revenue guidance to 20%-25%
Read More →

Champions Oncology Announces the Launch of Lumin Bioinformatics, Its New Oncology Data-Driven SaaS Program

Nov 17, 2020 12:36:06 PM / by Champions Oncology

HACKENSACK, NJ / ACCESSWIRE / November 16, 2020 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker and data platforms, announced today the launch of its new proprietary SaaS program known as Lumin Bioinformatics. By leveraging Champions' large cancer dataset, which is unique for its substantial depth of characterization, combined with many other published cancer datasets, Lumin provides users with a vast database of tumor characterization that can be used for computational research. The software, which is purchased as a yearly subscription, also provides sophisticated analytic tools that are utilized to interrogate the data for associations between molecular and various phenotypic features, including thousands of drug responses, clinical annotations, prior treatment histories, and genetic dependencies. Insights developed using Lumin can provide the basis for biomarker hypotheses, reveal potential mechanisms of therapeutic resistance, and guide the direction of additional preclinical evaluations.

Read More →